Ambys Medicines
Brendan Lee is the Robert and Janice McNair Endowed Chair, Professor, and Chairman of the Department of Molecular and Human Genetics, Director of the Center for Skeletal Medicine and Biology at Baylor College of Medicine, and Co-Director of the Texas Medical Center Bone Disease Program of Texas. As a pediatrician and geneticist, Brendan studies structural birth defects and inborn errors of metabolism. Brendan identified the first genetic causes of human skeletal dysplasias and their implications for cancers of the skeleton. In the area of metabolic disease, he has studied nitric oxide dysregulation and developed new treatments for maple syrup urine disease and urea cycle disorders.
Brendan earned his B.S. from City University of New York, Brooklyn College, his Ph.D. from State University of New York Downstate Medical Center, and his M.D. from State University of New York Downstate Medical Center.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.